A Phase 3 interventional study of G-Pen and Lilly Glucagon in Insulin Hypoglycemia, Type 1 Diabetes Mellitus and Severe Hypoglycemia, sponsored by Xeris Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Xeris Pharmaceuticals · Phase 3, Interventional, and Treatment
Among 34 studies testing glucagon in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Glucagon · Diabetes Mellitus, Type 1.
Among the 34 studies testing glucagon in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 7 in phase 3, and was the 23rd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 81 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →1 of the 34 studies testing glucagon in Diabetes Mellitus, Type 1 is open now, in 1 country. Each count lists the studies.
Glucagon: first FDA approval 1960 (GLUCAGON), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 411 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 257 (63%) stop at 75 or younger; 184 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2018.
Median enrollment 17 across the 34 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
14 of 34 have an industry lead sponsor. The 10 most frequent:
Xeris Pharmaceuticals is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
Xeris Pharmaceuticals has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing glucagon in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07427251Steno Diabetes Center CopenhagenThe Postprandial Hypo-Avoid Study | 2027-05-01 |
Among the 34 studies testing glucagon in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime clinical research center (CRC) visits with random assignment to receive G-Pen™ glucagon 1 mg during one period and Lilly Glucagon 1 mg during the other. Each daytime visit is preceded by an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is brought into a state of hypoglycemia through IV administration of regular insulin diluted in normal saline. After a hypoglycemic state with plasma glucose \< 50 mg/dL is verified, the subject is administered a dose of G-Pen or Lilly Glucagon via subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes post-dosing, with a value of >70.0 mg/dL within 30 minutes of glucagon administration indicating a positive response. After 3 hours, the subject is given a meal and discharged when medically stable. After a wash-out period of 7 to 28 days, subjects return to the CRC, and the procedure are repeated with each subject crossed over to the other treatment. A follow-up visit as a safety check is conducted 2-7 days following administration of the final dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
Drug: G-Pen · Drug: Lilly Glucagon
1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
Drug: G-Pen · Drug: Lilly Glucagon
1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Also known as: glucagon
1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
Also known as: GEK
Number of Subjects With a Positive Glucose Response
Increase in plasma glucose concentration from below 50.0 mg/dL to greater than 70.0 mg/dL within 30 minutes after receiving glucagon
Time frame: 0 to 30 minutes post dose
Time for Positive Glucose Response
Time from administration of glucagon for plasma glucose to rise from below 50.0 mg/dL to above 70.0 mg/dL
Time frame: 0 to 180 minutes post dose
Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase
A positive response for this endpoint is a return of plasma glucose to \> 70 mg/dL or an increase in plasma glucose by ≥20 mg/dL within 30 minutes after receiving glucagon
Time frame: 0 to 30 minutes post dose
Number of Subjects With a Positive Glucose Increase
Increase in plasma glucose by ≥ 20.0 mg/dL within 30 minutes after receiving glucagon
Time frame: 0 to 30 minutes post dose
Time for Positive Glucose Increase
Time from administration of glucagon for plasma glucose to increase by ≥20 mg/dL from baseline
Time frame: 0 to 180 minutes post dose
Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms
A positive response for this endpoint is a return of plasma glucose to \> 70 mg/dL or clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
Time frame: 0 to 30 minutes post dose
Number of Subjects With Relief of Neuroglycopenic Symptoms
Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
Time frame: 0 to 30 minutes post dose
Time to Resolution of Autonomic Symptoms
Time from administration of glucagon to complete resolution of 4 autonomic symptoms of hypoglycemia. Symptoms included: sweating, tremor, palpitations and feeling of nervousness.
Time frame: 0 to 180 minutes post dose
Time to Resolution of Neuroglycopenic Symptoms
Time from administration of glucagon to complete resolution of 4 neuroglycopenic symptoms of hypoglycemia. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
Time frame: 0 to 180 minutes post dose
Time to Resolution of the Feeling of Hypoglycemia
Time from administration of glucagon to resolution of the overall sensation of hypoglycemia. Subjects were asked to answer yes/no to the question, "Do you feel hypoglycemic?" The time point as which the subject first answered "no" was considered the time of resolution.
Time frame: 0 to 180 minutes post dose
Glucose AUC
Area under the curve for plasma glucose.
Time frame: 0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.
Glucose Cmax
Maximum concentration of plasma glucose.
Time frame: 0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.
Glucose Tmax
Time to maximum concentration of plasma glucose. Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.
Time frame: 0 to 180 minutes post dose
Glucagon Preparation and Administration Time
Time required to prepare and inject glucagon as measured between a "decision to dose" and completion of the injection
Time frame: 0 to 5 minutes pre-dose
The recruitment period began 08 Jan 2018 and ran through 02 Apr 2018. Subjects were screened for study eligibility at one of the six clinical sites up to 30 days prior to randomization.
| Milestone | G-Pen Followed by Lilly Glucagon | Lilly Glucagon Followed by G-Pen |
|---|---|---|
| Started | 41 | 40 |
| Completed | 39 | 36 |
| Not completed | 2 | 4 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 |
Increase in plasma glucose concentration from below 50.0 mg/dL to greater than 70.0 mg/dL within 30 minutes after receiving glucagon
| Participants | G-Pen | Lilly Glucagon |
|---|---|---|
| Number of Subjects With a Positive Glucose Response | 76 | 78 |
Time from administration of glucagon for plasma glucose to rise from below 50.0 mg/dL to above 70.0 mg/dL
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Time for Positive Glucose Response | 12.17 ± 3.604 | 8.58 ± 2.026 |
A positive response for this endpoint is a return of plasma glucose to \> 70 mg/dL or an increase in plasma glucose by ≥20 mg/dL within 30 minutes after receiving glucagon
| Participants | G-Pen | Lilly Glucagon |
|---|---|---|
| Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase | 76 | 78 |
Increase in plasma glucose by ≥ 20.0 mg/dL within 30 minutes after receiving glucagon
| Participants | G-Pen | Lilly Glucagon |
|---|---|---|
| Number of Subjects With a Positive Glucose Increase | 76 | 78 |
Time from administration of glucagon for plasma glucose to increase by ≥20 mg/dL from baseline
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Time for Positive Glucose Increase | 11.36 ± 3.345 | 8.02 ± 1.856 |
A positive response for this endpoint is a return of plasma glucose to \> 70 mg/dL or clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
| Participants | G-Pen | Lilly Glucagon |
|---|---|---|
| Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms | 76 | 78 |
Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
| Participants | G-Pen | Lilly Glucagon |
|---|---|---|
| Number of Subjects With Relief of Neuroglycopenic Symptoms | 74 | 77 |
Time from administration of glucagon to complete resolution of 4 autonomic symptoms of hypoglycemia. Symptoms included: sweating, tremor, palpitations and feeling of nervousness.
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Time to Resolution of Autonomic Symptoms | 13.8 ± 10.89 | 12.0 ± 7.44 |
Time from administration of glucagon to complete resolution of 4 neuroglycopenic symptoms of hypoglycemia. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Time to Resolution of Neuroglycopenic Symptoms | 14.2 ± 15.12 | 12.2 ± 8.85 |
Time from administration of glucagon to resolution of the overall sensation of hypoglycemia. Subjects were asked to answer yes/no to the question, "Do you feel hypoglycemic?" The time point as which the subject first answered "no" was considered the time of resolution.
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Time to Resolution of the Feeling of Hypoglycemia | 11.6 ± 6.45 | 13.1 ± 7.86 |
Area under the curve for plasma glucose.
| mg∙min/dL | G-Pen | Lilly Glucagon |
|---|---|---|
| Glucose AUC | 33686.04 ± 5300.204 | 33538.60 ± 5705.219 |
Maximum concentration of plasma glucose.
| mg/dL | G-Pen | Lilly Glucagon |
|---|---|---|
| Glucose Cmax | 238.32 ± 45.626 | 228.11 ± 46.567 |
Time to maximum concentration of plasma glucose. Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.
| minutes | G-Pen | Lilly Glucagon |
|---|---|---|
| Glucose Tmax | 125.67 ± 33.513 | 113.89 ± 31.908 |
Time required to prepare and inject glucagon as measured between a "decision to dose" and completion of the injection
| seconds | G-Pen | Lilly Glucagon |
|---|---|---|
| Glucagon Preparation and Administration Time | 27.3 ± 19.66 | 97.2 ± 45.06 |
Collected over Adverse events were collected for up to 9 weeks, from the time of consent through the follow-up visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-Pen | 0/76 (0%) | 0/76 (0%) | 46/76 (60.5%) |
| Lilly Glucagon | 0/78 (0%) | 0/78 (0%) | 34/78 (43.6%) |
| Event | G-Pen | Lilly Glucagon |
|---|---|---|
| NauseaGastrointestinal disorders | 29/76 | 26/78 |
| VomitingGastrointestinal disorders | 20/76 | 11/78 |
| HeadacheNervous system disorders | 6/76 | 4/78 |
All randomized subjects
| Age, Continuous(years) | All Randomized Subjects |
|---|---|
| Mean | 38.2 ± 14.6 |
| Sex: Female, Male(Participants) | All Randomized Subjects |
|---|---|
| Female | 37 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | All Randomized Subjects |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 75 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Randomized Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 71 |
| More than one race | 3 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | All Randomized Subjects |
|---|---|
| North America | 81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Apr 2018, 2 months.
Results were first posted in May 2019, 1 year 1 month after primary completion.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 2 months is below that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucagon
Xeris Pharmaceuticals